-$0.82 EPS Expected for Bicycle Therapeutics plc (NASDAQ:BCYC) This Quarter

Wall Street analysts expect that Bicycle Therapeutics plc (NASDAQ:BCYCGet Rating) will announce earnings of ($0.82) per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Bicycle Therapeutics’ earnings. The highest EPS estimate is ($0.67) and the lowest is ($1.15). Bicycle Therapeutics posted earnings of ($0.74) per share in the same quarter last year, which suggests a negative year over year growth rate of 10.8%. The business is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Bicycle Therapeutics will report full-year earnings of ($3.51) per share for the current fiscal year, with EPS estimates ranging from ($5.14) to ($2.77). For the next fiscal year, analysts anticipate that the firm will report earnings of ($4.09) per share, with EPS estimates ranging from ($6.19) to ($2.95). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) last released its earnings results on Thursday, May 5th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.23). The firm had revenue of $3.86 million during the quarter, compared to analyst estimates of $3.46 million. Bicycle Therapeutics had a negative net margin of 568.71% and a negative return on equity of 31.61%.

Several research firms have recently commented on BCYC. TheStreet cut Bicycle Therapeutics from a “c-” rating to a “d+” rating in a research note on Thursday, April 21st. Zacks Investment Research raised Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 9th. Morgan Stanley initiated coverage on Bicycle Therapeutics in a research note on Monday, February 14th. They set an “equal weight” rating and a $60.00 price objective for the company. Piper Sandler decreased their price objective on Bicycle Therapeutics from $76.00 to $37.00 and set an “overweight” rating for the company in a research note on Monday, May 23rd. Finally, JMP Securities reaffirmed a “buy” rating and set a $70.00 price objective on shares of Bicycle Therapeutics in a research note on Monday. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $61.83.

NASDAQ BCYC opened at $15.13 on Wednesday. The stock has a fifty day moving average of $23.83 and a 200-day moving average of $40.63. The stock has a market capitalization of $448.54 million, a P/E ratio of -5.24 and a beta of 0.60. Bicycle Therapeutics has a 52 week low of $13.68 and a 52 week high of $62.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.14 and a current ratio of 12.14.

Large investors have recently bought and sold shares of the business. Deep Track Capital LP acquired a new position in Bicycle Therapeutics in the fourth quarter valued at about $66,957,000. Shilanski & Associates Inc. bought a new stake in shares of Bicycle Therapeutics in the fourth quarter valued at about $314,000. LMR Partners LLP bought a new stake in shares of Bicycle Therapeutics in the fourth quarter valued at about $2,435,000. Personal CFO Solutions LLC lifted its holdings in shares of Bicycle Therapeutics by 3.7% in the third quarter. Personal CFO Solutions LLC now owns 7,558 shares of the company’s stock valued at $314,000 after purchasing an additional 273 shares in the last quarter. Finally, Claro Advisors LLC bought a new stake in shares of Bicycle Therapeutics in the fourth quarter valued at about $221,000. 71.99% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile (Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Featured Stories

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bicycle Therapeutics (NASDAQ:BCYC)

Want More Great Investing Ideas?

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.